%	O
%	O
TITLE	O

Oral	O
gargle	O
-	O
tumor	O
biopsy	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
agreement	O
and	O
associated	O
factors	O
among	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
OPSCC	O
)	O
cases	O
.	O

%	O
%	O
ABSTRACT	O

Assess	O
oral	O
gargle	O
-	O
tumor	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
agreement	O
among	O
oropharyngeal	O
squamous	O
cell	O
carcinoma	O
(	O
OPSCC	O
)	O
cases	O
by	O
several	O
disease	O
characteristics	O
.	O
171	B-Study_Cohort
treatment	I-Study_Cohort
naÃ¯ve	I-Study_Cohort
OPSCC	I-Study_Cohort
were	O
enrolled	O
2014	B-Study_Time
-	I-Study_Time
2017	I-Study_Time
.	O

Tumors	O
were	O
categorized	O
as	O
early	O
or	O
late	O
disease	O
with	O
early	O
disease	O
defined	O
as	O
T1	O
-	O
2	O
with	O
no	O
nodal	O
involvement	O
or	O
at	O
most	O
a	O
single	O
ipsilateral	O
positive	O
node	O
<	O
3â€¯cm	O
.	O

Oral	O
gargle	O
samples	B-HPV_Sample_Type
were	O
obtained	O
via	O
a	O
30	B-HPV_Sample_Collection_Method
-	I-HPV_Sample_Collection_Method
second	I-HPV_Sample_Collection_Method
rinse	I-HPV_Sample_Collection_Method
and	I-HPV_Sample_Collection_Method
gargle	I-HPV_Sample_Collection_Method
.	O

The	O
RHA	O
Kit	O
HPV	O
SP83	O
.	O
0	O
%	O
and	O
93	O
.	O
0	O
%	O
of	O
oral	O
gargle	O
and	O
tumor	O
specimens	B-HPV_Sample_Type
were	O
HPV	O
positive	O
.	O

Oral	O
gargle	O
-	O
tumor	O
agreement	O
for	O
any	O
oncogenic	O
HPV	O
type	O
and	O
HPV	O
16	O
was	O
73	O
.	O
7	O
%	O
.	O

High	O
oncogenic	O
HPV	O
oral	O
gargle	O
-	O
tumor	O
agreement	O
was	O
observed	O
for	O
late	O
disease	O
presentation	O
,	O
p16	O
positive	O
cases	O
,	O
and	O
tumors	O
at	O
the	O
tonsils	O
(	O
74	O
.	O
5	O
-	O
80	O
.	O
8	O
%	O
)	O
.	O

Similar	O
trends	O
were	O
observed	O
for	O
HPV	O
16	O
.	O

Agreement	O
for	O
any	O
oncogenic	O
HPV	O
and	O
HPV	O
16	O
was	O
significantly	O
higher	O
for	O
late	O
vs	O
.	O
early	O
disease	O
(	O
77	O
.	O
9	O
%	O
vs	O
57	O
.	O
1	O
%	O
,	O
pâ€¯=â€¯0	O
.	O
01	O
)	O
.	O

Oral	O
gargle	O
-	O
tumor	O
oncogenic	O
HPV	O
and	O
HPV	O
16	O
agreement	O
was	O
independently	O
associated	O
with	O
age	O
â‰¥50â€¯years	O
and	O
late	O
disease	O
presentation	O
.	O
Overall	O
,	O
oral	O
-	O
tumor	O
HPV	O
agreement	O
among	O
OPSCC	O
was	O
relatively	O
high	O
.	O

However	O
,	O
oral	O
-	O
tumor	O
HPV	O
agreement	O
was	O
significantly	O
lower	O
among	O
younger	O
cases	O
and	O
those	O
diagnosed	O
with	O
earlier	O
disease	O
.	O

Additional	O
biomarkers	O
are	O
needed	O
to	O
improve	O
oral	O
HPV	O
test	O
characteristics	O
to	O
identify	O
OPSCC	O
early	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Study	O
participants	O

One	B-Study_Cohort
-	I-Study_Cohort
hundred	I-Study_Cohort
and	I-Study_Cohort
seventy	I-Study_Cohort
-	I-Study_Cohort
one	I-Study_Cohort
men	I-Study_Cohort
with	I-Study_Cohort
newly	I-Study_Cohort
diagnosed	I-Study_Cohort
,	I-Study_Cohort
histolo	I-Study_Cohort
-	I-Study_Cohort
gically	I-Study_Cohort
conﬁrmed	I-Study_Cohort
and	I-Study_Cohort
treatment	I-Study_Cohort
naïve	I-Study_Cohort
OPSCC	I-Study_Cohort
of	O
all	O
stages	O
were	O
en	O
-	O
rolled	O
to	O
an	O
ongoing	O
biomarker	O
study	O
at	O
the	O
Moﬃtt	O
Cancer	O
Center	O
(	O
Tampa	O
,	O
Florida	O
)	O
between	O
May	B-Study_Time
2014	I-Study_Time
and	I-Study_Time
October	I-Study_Time
2017	I-Study_Time
.	O

At	O
the	O
time	O
of	O
recruitment	O
,	O
all	O
participants	O
completed	O
a	O
health	O
and	O
risk	O
factor	O
ques	O
-	O
tionnaire	O
and	O
provided	O
an	O
oral	O
gargle	O
sample	B-HPV_Sample_Type
.	I-HPV_Sample_Type

Formalin	O
-	O
ﬁxed	O
paraﬃn	O
-	O
embedded	O
(	O
FFPE	O
)	O
tumor	O
samples	B-HPV_Sample_Type
were	O
retrieved	O
for	O
all	O
participants	O
and	O
staging	O
and	O
treatment	O
data	O
were	O
accessed	O
through	O
the	O
review	O
of	O
elec	O
-	O
tronic	O
medical	O
records	O
.	O

This	O
study	O
was	O
approved	O
by	O
the	O
Liberty	O
IRB	O
,	O
Chesapeake	O
IRB	O
,	O
and	O
Moﬃtt’s	O
Scientiﬁc	O
Review	O
Committee	O
,	O
and	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
enrolled	O
participants	O
.	O

Data	O
and	O
sample	B-HPV_Sample_Type
collection	O

All	O
participants	O
completed	O
a	O
computer	O
assisted	O
self	O
-	O
administered	O
interview	O
(	O
CASI	O
)	O
questionnaire	O
at	O
the	O
time	O
of	O
enrollment	O
.	O

Information	O
was	O
obtained	O
on	O
general	O
demographics	O
,	O
medical	O
and	O
family	O
history	O
of	O
cancer	O
,	O
sexual	O
history	O
,	O
oral	O
health	O
,	O
and	O
risk	O
behavior	O
.	O

Tumors	O
were	O
divided	O
into	O
two	O
categories	O
–	O
early	O
or	O
late	O
extent	O
of	O
disease	O
according	O
to	O
the	O
tumor	O
burden	O
at	O
the	O
time	O
of	O
diagnosis	O
;	O
whereby	O
,	O
early	O
disease	O
in	O
-	O
cluded	O
tumors	O
diagnosed	O
as	O
T1	O
-	O
2	O
with	O
no	O
nodal	O
involvement	O
or	O
at	O
most	O
a	O
single	O
ipsilateral	O
positive	O
node	O
<	O
3	O
cm	O
,	O
while	O
all	O
other	O
cases	O
were	O
considered	O
late	O
disease	O
.	O

This	O
classiﬁcation	O
is	O
used	O
to	O
determine	O
treat	O
-	O
ment	O
–	O
either	O
monotherapy	O
or	O
multiple	O
modality	O
therapy	O
(	O
e	O
.	O
g	O
.	O
,	O
che	O
-	O
moradiation	O
±	O
surgery	O
)	O
.	O

Oral	O
gargle	O
samples	B-HPV_Sample_Type
were	O
obtained	O
from	O
each	O
participant	O
by	O
use	O
of	O
a	O
30	B-HPV_Sample_Collection_Method
-	I-HPV_Sample_Collection_Method
second	I-HPV_Sample_Collection_Method
rinse	I-HPV_Sample_Collection_Method
and	I-HPV_Sample_Collection_Method
gargle	I-HPV_Sample_Collection_Method
method	O
with	O
15	O
mL	O
of	O
locally	O
available	O
mouthwash	O
as	O
described	O
previously	O
.	O

Samples	B-HPV_Sample_Type
were	O
then	O
cen	O
-	O
trifuged	O
at	O
3000g	O
for	O
15	O
min	O
at	O
4	O
°C	O
three	O
times	O
.	O

The	O
ﬁnal	O
cell	O
pellet	O
was	O
resuspended	O
in	O
phosphate	O
buﬀered	O
saline	O
(	O
PBS	O
)	O
and	O
frozen	O
at	O
−80	O
°C	O
within	O
24	O
h	O
of	O
collection	O
.	O

DNA	O
extraction	O
from	O
oral	O
gargle	O
and	O
tumor	O
samples	B-HPV_Sample_Type

DNA	O
was	O
extracted	O
from	O
the	O
oral	O
gargle	O
cell	O
pellets	O
using	O
the	O
au	O
-	O
tomated	O
BioRobot	O
MDx	O
(	O
Qiagen	O
,	O
Inc	O
.	O
)	O
following	O
the	O
manufacturer’s	O
instructions	O
.	O

For	O
the	O
extraction	O
of	O
DNA	O
from	O
FFPE	O
tumor	O
samples	B-HPV_Sample_Type
the	O
QIAamp®	O
DNA	O
FFPE	O
Tissue	O
Kit	O
(	O
Qiagen	O
,	O
Inc	O
.	O
)	O
was	O
used	O
according	O
to	O
the	O
manufacturer’s	O
instructions	O
.	O

HPV	B-HPV_Lab_Technique
genotyping	I-HPV_Lab_Technique

The	B-HPV_Lab_Technique
RHA	I-HPV_Lab_Technique
Kit	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
SP10	I-HPV_Lab_Technique
-	I-HPV_Lab_Technique
LiPA25	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
DDL	I-HPV_Lab_Technique
Diagnostic	I-HPV_Lab_Technique
Laboratory	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
Rijswijk	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
The	I-HPV_Lab_Technique
Netherlands	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
,	I-HPV_Lab_Technique
an	I-HPV_Lab_Technique
in	I-HPV_Lab_Technique
vitro	I-HPV_Lab_Technique
reverse	I-HPV_Lab_Technique
hybridization	I-HPV_Lab_Technique
assay	I-HPV_Lab_Technique
(	I-HPV_Lab_Technique
RHA	I-HPV_Lab_Technique
)	I-HPV_Lab_Technique
for	I-HPV_Lab_Technique
the	I-HPV_Lab_Technique
qualitative	I-HPV_Lab_Technique
identiﬁcation	I-HPV_Lab_Technique
of	I-HPV_Lab_Technique
HPV	I-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique
,	O
was	O
utilized	O
for	O
HPV	O
genotyping	O
of	O
tumor	O
and	O
oral	O
gargle	O
specimens	B-HPV_Sample_Type
.	O

The	O
LiPA25	O
test	O
targets	O
a	O
65	O
base	O
pair	O
fragment	O
of	O
the	O
L1	O
region	O
of	O
the	O
HPV	O
genome	O
.	O

This	O
assay	O
requires	O
a	O
three	O
step	O
process	O
:	O
(	O
1	O
)	O
qPCR	B-HPV_Lab_Technique
that	O
determines	O
sample	B-HPV_Sample_Type
adequacy	O
;	O
(	O
2	O
)	O
a	O
DNA	O
enzyme	O
immunoassay	O
(	O
DEIA	O
)	O
or	O
ELISA	O
method	O
that	O
detects	O
the	O
presence	O
of	O
the	O
following	O
HPV	O
types	O
:	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
11	O
,	O
13	O
,	O
14	O
,	O
16	O
,	O
18	O
,	O
20	O
,	O
26	O
,	O
27	O
,	O
28	O
,	O
30	O
,	O
31	O
,	O
32	O
,	O
33	O
,	O
34	O
,	O
35	O
,	O
37	O
,	O
39	O
,	O

40	O
,	O
42	O
,	O
43	O
,	O
44	O
,	O
45	O
,	O
55	O
,	O
56	O
,	O
57	O
,	O
58	O
,	O
59	O
,	O
61	O
,	O
62	O
,	O
64	O
,	O
65	O
,	O
66	O
,	O
67	O
,	O
68	O
,	O
69	O
,	O
70	O
,	O

71	O
,	O
72	O
,	O
73	O
,	O
74	O
,	O
75	O
,	O
76	O
,	O
81	O
,	O
82	O
,	O
83	O
,	O
84	O
,	O
85	O
,	O
86	O
,	O
87	O
,	O
89	O
,	O
90	O
,	O
91	O
,	O
95	O
,	O
97	O
,	O
102	O
,	O

106	O
,	O
114	O
and	O
115	O
;	O
and	O
(	O
3	O
)	O
a	O
LiPA25	O
genotyping	O
multiplex	B-HPV_Lab_Technique
PCR	I-HPV_Lab_Technique
that	O
selectively	O
identiﬁes	O
the	O
following	O
HPV	O
types	O
by	O
reverse	O
hybridization	O
:	O
6	O
,	O
11	O
,	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
34	O
,	O
35	O
,	O
39	O
,	O
40	O
,	O
42	O
,	O
43	O
,	O
44	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
53	O
,	O
54	O
,	O
56	O
,	O

58	O
,	O
59	O
,	O
66	O
,	O
68	O
/	O
73	O
,	O
70	O
,	O
and	O
74	O
.	O

Oncogenic	O
HPV	O
types	O
included	O
HPV	O

16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
56	O
,	O
58	O
,	O
59	O
,	O
and	O
68	O
.	O

The	O
LiPA25	O
assay	O

has	O
proven	O
to	O
detect	O
up	O
to	O
20	O
%	O
more	O
HPV	O
types	O
than	O
other	O
marketed	O
assays	O
,	O
making	O
it	O
the	O
most	O
sensitive	O
assay	O
for	O
samples	B-HPV_Sample_Type
with	O
low	O
copy	O
number	O
and	O
/	O
or	O
mixed	O
-	O
type	O
HPV	O
samples	B-HPV_Sample_Type
like	O
those	O
obtained	O
in	O
oral	O
gargles	O
.	O

Using	O
this	O
method	O
,	O
our	O
group	O
has	O
reliably	O
identiﬁed	O
HPV	O
types	O
in	O
ano	O
-	O
genital	O
mucosa	O
as	O
well	O
as	O
oral	O
gargle	O
speci	O
-	O
mens	O
.	O

Pathology	O
review	O
and	O
immunohistochemistry	B-HPV_Lab_Technique

Slides	O
from	O
FFPE	O
blocks	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
(	O
H	O
&	O
E	O
)	O
and	O
p16INK4a	O
(	O
p16	O
)	O
.	O

p16	O
staining	O
was	O
missing	O
for	O
5	O
of	O
the	O
171	O
cases	O
.	O

Two	O
expert	O
pathologists	O
independently	O
classiﬁed	O
and	O
graded	O
the	O
tumors	O
and	O
completed	O
the	O
visual	O
morphometric	O
analysis	O
blinded	O
to	O
HPV	O
genotyping	O
results	O
.	O

p16	O
was	O
considered	O
positive	O
when	O
>	O
70	O
%	O
of	O
the	O
cells	O
had	O
strong	O
and	O
diﬀuse	O
nuclear	O
and	O
cytoplasmic	O
staining	O
.	O

Statistical	O
analysis	O

Participant	O
characteristics	O
were	O
summarized	O
using	O
descriptive	O
sta	O
-	O
tistics	O
including	O
median	O
and	O
range	O
for	O
continuous	O
measures	O
,	O
and	O
pro	O
-	O
portions	O
and	O
frequencies	O
for	O
categorical	O
measures	O
.	O

Agreement	O
between	O
oral	O
gargle	O
and	O
tumor	O
HPV	O
status	O
were	O
considered	O
for	O
any	O
oncogenic	O
HPV	O
(	O
type	O
speciﬁc	O
grouped	O
infection	O
)	O
and	O
HPV	O
16	O
.	O

Considering	O
tumor	O
status	O
as	O
gold	O
standard	O
or	O
truth	O
,	O
sensitivity	O
,	O
speciﬁcity	O
,	O
positive	O
and	O
negative	O
predictive	O
value	O
(	O
PPV	O
and	O
NPV	O
)	O
were	O
calculated	O
along	O
with	O
percent	O
agreement	O
,	O
with	O
the	O
95	O
%	O
exact	O
binomial	O
conﬁdence	O
interval	O
estimated	O
,	O
and	O
p	O
values	O
from	O
the	O
McNemar’s	O
test	O
.	O

Individual	O
logistic	O
regression	O
models	O
were	O
ﬁt	O
to	O
predict	O
agreement	O
,	O

followed	O
by	O
multivariable	O
logistic	O
regression	O
model	O
using	O
stepwise	O
se	O
-	O
lection	O
.	O

Of	O
note	O
,	O
race	O
and	O
ethnicity	O
were	O
not	O
considered	O
in	O
multi	O
-	O
variable	O
models	O
due	O
to	O
sparse	O
sampling	O
,	O
along	O
with	O
their	O
unimportance	O
in	O
univariate	O
modeling	O
.	O

Tumor	O
subsite	O
was	O
not	O
considered	O
in	O
any	O
modeling	O
,	O
due	O
to	O
its	O
sparse	O
sampling	O
,	O
speciﬁcally	O
in	O
the	O
soft	O
palate	O
ca	O
-	O
tegory	O
.	O

Due	O
to	O
the	O
exploratory	O
nature	O
of	O
this	O
analysis	O
,	O
p	O
-	O
values	O
were	O
not	O
adjusted	O
for	O
multiple	O
comparisons	O
.	O

All	O
statistical	O
analyses	O
were	O
per	O
-	O
formed	O
using	O
R	O
version	O
3	O
.	O
5	O
.	O

1	O
(	O
The	O
R	O
Foundation	O
)	O
.	O

Table	O
1	O

Study	O
participant	O
characteristics	O
.	O

No	O
71	O
(	O
42	O
.	O
0	O
%	O
)	O

Yes	O
98	O
(	O
58	O
.	O
0	O
%	O
)	O

Cigarette	O
Pack	O
-	O
Years	O
,	O
median	O
(	O
range	O
)	O
20	O
.	O
0	O
[	O
0	O
.	O
0	O
;	O
84	O
.	O

0	O
]	O
Cigarette	O
Pack	O
-	O
Years	O
:	O

Results	O

OPSCC	O
participant	O
demographic	O
and	O
behavioral	O
characteristics	O

The	O
majority	O
of	O
OPSCC	O
participants	O
were	O
white	O
(	O
93	O
.	O
0	O
%	O
)	O
,	O
non	O
-	O
Hispanic	O
(	O
92	O
.	O
4	O
%	O
)	O
with	O
a	O
median	O
age	O
of	O
61	O
years	O
.	O

Seventy	O
-	O
four	O
percent	O
were	O
either	O
married	O
or	O
cohabiting	O
at	O
the	O
time	O
of	O
enrollment	O
and	O
73	O
.	O
6	O
%	O
had	O
at	O
least	O
some	O
college	O
education	O
.	O

Fifty	O
-	O
eight	O
percent	O
of	O
OPSCC	O
participants	O
were	O
either	O
current	O
or	O
former	O
smokers	O
.	O

Most	O
cases	O
(	O
59	O
.	O
2	O
%	O
)	O
reported	O
having	O
any	O
alcohol	O
consumption	O
in	O
the	O
previous	O
month	O
with	O
45	O
.	O
5	O
%	O
reporting	O
consumption	O
of	O
1–4	O
alcoholic	O
drinks	O
per	O
drinking	O
oc	O
-	O
casion	O
,	O
and	O
12	O
.	O
6	O
%	O
reported	O
having	O
≥5	O
alcoholic	O
drinks	O
per	O
drinking	O
occasion	O
within	O
the	O
past	O
month	O
.	O

Approximately	O
40	O
%	O
reported	O
giving	O
oral	O
sex	O
in	O
the	O
prior	O
6	O
months	O
.	O

Nearly	O
half	O
(	O
45	O
.	O
8	O
%	O
)	O
reported	O
undergoing	O
a	O
tonsillectomy	O
prior	O
to	O
diagnosis	O
,	O
and	O
of	O
the	O
men	O
that	O
had	O
a	O
tonsil	O
-	O
lectomy	O
,	O
81	O
.	O
6	O
%	O
had	O
the	O
procedure	O
completed	O
more	O
than	O
10	O
years	O
prior	O
to	O
cancer	O
diagnosis	O
(	O
)	O
.	O

Tumor	O
and	O
pathological	O
characteristics	O

The	O
majority	O
of	O
OPSCC	O
cases	O
had	O
tumors	O
located	O
in	O
either	O
the	O
base	O
of	O
tongue	O
(	O
49	O
.	O
1	O
%	O
)	O
or	O
the	O
palatine	O
tonsils	O
or	O
tonsillar	O
fossa	O
(	O
45	O
.	O
6	O
%	O
)	O
.	O

The	O
remaining	O
5	O
.	O
3	O
%	O
had	O
tumors	O
located	O
at	O
other	O
sites	O
within	O
the	O
or	O
-	O
opharynx	O
including	O
the	O
soft	O
palate	O
.	O

p16	O
was	O
evaluated	O
in	O
166	O
/	O
171	O
OPSCC	O
participants	O
.	O

Of	O
these	O
,	O
92	O
.	O
2	O
%	O
had	O
tumors	O
that	O
stained	O
positive	O
for	O
p16	O
.	O

Staging	O
was	O
assessed	O
at	O
the	O
time	O
of	O
diagnosis	O
using	O
the	O
AJCC	O
-	O
7th	O
edition	O
and	O
converted	O
to	O
AJCC	O
-	O
8th	O
edition	O
according	O
to	O
p16	O
in	O
-	O
volvement	O
for	O
this	O
study	O
.	O

Among	O
the	O
p16	O
positive	O
cases	O
,	O
85	O
(	O
51	O
.	O
2	O
%	O
)	O
were	O
stage	O
I	O
and	O
68	O
(	O
41	O
.	O
0	O
%	O
)	O
were	O
either	O
stage	O
II	O
or	O
III	O
at	O
diagnosis	O
.	O

Of	O
the	O
thirteen	O
p16	O
negative	O
cases	O
,	O
four	O
were	O
stage	O
I	O
/	O
II	O
and	O
nine	O
were	O
stage	O
III	O
/	O
IV	O
at	O
diagnosis	O
.	O

When	O
grouped	O
according	O
to	O
the	O
deﬁnition	O
of	O
early	O
vs	O
late	O
disease	O
,	O
nearly	O
80	O
%	O
presented	O
as	O
late	O
disease	O
at	O
the	O
time	O
of	O
diag	O
-	O
nosis	O
(	O
)	O
.	O

HPV	O
genotype	O
proﬁle	O

HPV	O
DNA	O
(	O
any	O
genotype	O
)	O
was	O
detected	O
in	O
83	O
.	O
0	O
%	O
and	O
93	O
.	O
0	O
%	O
of	O
the	O
oral	O
gargle	O
and	O
tumor	O
biopsy	B-HPV_Sample_Type
specimens	B-HPV_Sample_Type
,	O
respectively	O
.	O

Among	O
the	O
oral	O
gargle	O
specimens	B-HPV_Sample_Type
,	O
74	O
.	O
9	O
%	O
were	O
positive	O
for	O
one	O
or	O
more	O
of	O
25	O
HPV	O
types	O
genotyped	O
by	O
the	O
LiPA25	O
assay	O
.	O

Overall	O
,	O
73	O
.	O
7	O
%	O
were	O
positive	O
for	O
an	O
oncogenic	O
HPV	O
type	O
(	O
64	O
.	O
3	O
%	O
were	O
HPV	O
16	O
positive	O
)	O
and	O
6	O
.	O
4	O
%	O
for	O
a	O
non	O
-	O
oncogenic	O
HPV	O
type	O
.	O

Among	O
the	O
tumor	O
specimens	B-HPV_Sample_Type
,	O
92	O
.	O
4	O
%	O
were	O
positive	O
for	O
one	O
or	O
more	O
of	O
25	O
HPV	O
types	O
genotyped	O
,	O
91	O
.	O
8	O
%	O
were	O
positive	O
for	O
an	O
oncogenic	O
HPV	O
type	O
(	O
83	O
.	O
6	O
%	O
HPV	O
16	O
positive	O
)	O
,	O
and	O
1	O
.	O
8	O
%	O
for	O
a	O
non	O
-	O
oncogenic	O
type	O
(	O
)	O
.	O

In	O
addition	O
to	O
HPV	O
16	O
,	O
HPV	O
18	O
(	O
4	O
.	O
1	O
%	O
for	O
both	O
specimens	O
)	O
,	O
HPV	O
33	O
(	O
4	O
.	O
7	O
%	O
and	O
7	O
.	O
0	O
%	O
,	O
oral	O
and	O
tumor	O
specimens	B-HPV_Sample_Type
re	O
-	O
spectively	O
)	O
,	O
and	O
HPV	O
35	O
(	O
2	O
.	O
9	O
%	O
and	O
4	O
.	O
1	O
%	O
,	O
oral	O
and	O
tumor	O
specimens	B-HPV_Sample_Type
respectively	O
)	O
were	O
detected	O
.	O

All	O
other	O
oncogenic	O
HPV	O
types	O
were	O
either	O
not	O
detected	O
or	O
detected	O
at	O
<	O
3	O
%	O
in	O
both	O
specimen	B-HPV_Sample_Type
types	O
(	O
data	O
not	O
shown	O
)	O
.	O

Due	O
to	O
the	O
exceedingly	O
low	O
sample	B-HPV_Sample_Type
size	O
for	O
individual	O
HPV	O
types	O
other	O
than	O
HPV	O
16	O
,	O
we	O
do	O
not	O
report	O
tumor	O
-	O
oral	O
gargle	O
agree	O
-	O
ment	O
.	O

Early	O
or	O
Late	O
Disease	O
Presentation	O
:	O

Early	O
(	O
T1	O
-	O
2	O
with	O
only	O
a	O
single	O
ipsilateral	O
positive	O
node	O

<	O
3	O
cm	O
or	O
less	O
)	O

35	O
(	O
20	O
.	O
5	O
%	O
)	O

HPV	O
agreement	O
between	O
oral	O
gargle	O
and	O
tumor	O
specimens	O

The	O
overall	O
oral	O
gargle	O
-	O
tumor	O
agreement	O
for	O
any	O
oncogenic	O
HPV	O
type	O
was	O
73	O
.	O
7	O
%	O
(	O
)	O
.	O

Agreement	O
was	O
highest	O
among	O
late	O
(	O
77	O
.	O
9	O
%	O
)	O
disease	O
presentation	O
cases	O
,	O
for	O
p16	O
positive	O
tumors	O
(	O
74	O
.	O
5	O
%	O
)	O
,	O
and	O
ton	O
-	O
sillar	O
tumors	O
(	O
80	O
.	O
8	O
%	O
)	O
.	O

The	O
percent	O
agreement	O
was	O
signiﬁcantly	O
higher	O
for	O
late	O
disease	O
cases	O
compared	O
to	O
early	O
disease	O
cases	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

The	O
overall	O
oral	O
gargle	O
-	O
tumor	O
HPV	O
16	O
agreement	O
was	O
73	O
.	O
7	O
%	O

Late	O
136	O
(	O
79	O
.	O
5	O
%	O
)	O

*	O
p16	O
was	O
evaluated	O
in	O
166	O
/	O
171	O
OPSCC	O
participants	O
.	O

(	O
)	O
.	O

As	O
with	O
oncogenic	O
HPV	O
oral	O
-	O
tumor	O
agreement	O
,	O
HPV	O
16	O
agreement	O
was	O
highest	O
among	O
late	O
(	O
77	O
.	O
9	O
%	O
)	O
disease	O
presentation	O
cases	O
,	O
among	O
p16	O
positive	O
tumors	O
(	O
73	O
.	O
9	O
%	O
)	O
,	O
and	O
tonsillar	O
tumors	O
(	O
78	O
.	O
2	O
%	O
)	O
.	O

Si	O
-	O
milarly	O
,	O
the	O
percent	O
HPV	O
16	O
agreement	O
was	O
signiﬁcantly	O
higher	O
for	O
late	O
disease	O
cases	O
compared	O
to	O
early	O
disease	O
cases	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

Fig	O
.	O

1	O
.	O

Tumor	O
-	O
oral	O
gargle	O
HPV	O
status	O
among	O
or	O
-	O
opharyngeal	O
cancer	O
cases	O
.	O

HPV	O
+	O
=	O
positive	O
for	O
one	O
or	O
more	O
HPV	O
types	O
2	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
,	O
11	O
,	O
13	O
,	O
14	O
,	O
16	O
,	O

18	O
,	O
20	O
,	O
26	O
,	O
27	O
,	O
28	O
,	O
30	O
,	O
31	O
,	O
32	O
,	O
33	O
,	O
34	O
,	O
35	O
,	O
37	O
,	O
39	O
,	O
40	O
,	O

42	O
,	O
43	O
,	O
44	O
,	O
45	O
,	O
55	O
,	O
56	O
,	O
57	O
,	O
58	O
,	O
59	O
,	O
61	O
,	O
62	O
,	O
64	O
,	O
65	O
,	O
66	O
,	O

67	O
,	O
68	O
,	O
69	O
,	O
70	O
,	O
71	O
,	O
72	O
,	O
73	O
,	O
74	O
,	O
75	O
,	O
76	O
,	O
81	O
,	O
82	O
,	O
83	O
,	O
84	O
,	O

85	O
,	O
86	O
,	O
87	O
,	O
89	O
,	O
90	O
,	O
91	O
,	O
95	O
,	O
97	O
,	O
102	O
,	O
106	O
,	O
114	O
and	O
115	O
.	O

Any	O
1	O
/	O
25	O
HPV	O
types	O
=	O
HPV	O
types	O
6	O
,	O
11	O
,	O
16	O
,	O
18	O
,	O
31	O
,	O

33	O
,	O
34	O
,	O
35	O
,	O
39	O
,	O
40	O
,	O
42	O
,	O
43	O
,	O
44	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O
53	O
,	O
54	O
,	O
56	O
,	O

58	O
,	O
59	O
,	O
66	O
,	O
68	O
/	O
73	O
,	O
70	O
,	O
and	O
74	O
.	O

Any	O
Oncogenic	O
HPV	O

types	O
=	O
HPV	O
types	O
16	O
,	O
18	O
,	O
31	O
,	O
33	O
,	O
35	O
,	O
39	O
,	O
45	O
,	O
51	O
,	O
52	O
,	O

56	O
,	O
58	O
,	O
59	O
,	O
68	O
.	O

Any	O
Non	O
-	O
Oncogenic	O
HPV	O

types	O
=	O
HPV	O
types	O
6	O
,	O
11	O
,	O
34	O
,	O
40	O
,	O
42	O
,	O
43	O
,	O
44	O
,	O
53	O
,	O
54	O
,	O

66	O
,	O
70	O
,	O
74	O
.	O

Diagnostic	O
performance	O
of	O
oral	O
gargle	O
HPV	O
detection	O

Using	O
oncogenic	O
HPV	O
detection	O
in	O
tumor	O
specimens	B-HPV_Sample_Type
as	O
the	O
gold	O
standard	O
,	O
the	O
sensitivity	O
and	O
speciﬁcity	O
were	O
75	O
.	O
8	O
%	O
and	O
50	O
.	O
0	O
%	O
,	O
re	O
-	O
spectively	O
(	O
)	O
.	O

The	O
PPV	O
and	O
NPV	O
for	O
oral	O
oncogenic	O
HPV	O
were	O
94	O
.	O
4	O
%	O
and	O
15	O
.	O
6	O
%	O
,	O
respectively	O
.	O

Sensitivity	O
was	O
higher	O
for	O
late	O
disease	O
cases	O
(	O
80	O
.	O
2	O
%	O
vs	O
58	O
.	O
1	O
%	O
)	O
,	O
p16	O
positive	O
cases	O
(	O
77	O
.	O
9	O
%	O
vs	O
.	O
28	O
.	O
6	O
%	O
)	O
,	O
and	O
tumors	O
originating	O
in	O
the	O
tonsils	O
(	O
84	O
.	O
9	O
%	O
vs	O
68	O
.	O
8	O
%	O
for	O
base	O
of	O
tongue	O
,	O
and	O
57	O
.	O
1	O
%	O
for	O
soft	O
palate	O
)	O
;	O
whereas	O
,	O
speciﬁcity	O
did	O
not	O
diﬀer	O
by	O
early	O
or	O
late	O
disease	O
(	O
50	O
%	O
)	O
,	O
was	O
highest	O
among	O
p16	O
negative	O
tumors	O
(	O
100	O
%	O
vs	O
.	O
12	O
.	O
5	O
%	O
)	O
and	O
tumors	O
originating	O
in	O
the	O
soft	O
palate	O
(	O
100	O
%	O
vs	O
.	O
57	O
.	O
1	O
%	O
base	O
of	O
tongue	O
,	O
and	O
20	O
%	O
tonsil	O
)	O
although	O
the	O
number	O
of	O
p16	O
negative	O
and	O
soft	O
palate	O
cases	O
was	O
small	O
.	O

Similar	O
results	O
were	O
observed	O
for	O
HPV	O
16	O
analyses	O
with	O
the	O
exception	O
that	O
speciﬁcity	O
(	O
78	O
.	O
6	O
%	O
HPV	O
16	O
vs	O
.	O
50	O
.	O
0	O
%	O
oncogenic	O
HPV	O
)	O
and	O
the	O
NPV	O
(	O
36	O
.	O
1	O
%	O
HPV	O
16	O
vs	O
.	O
15	O
.	O
6	O
%	O
oncogenic	O
HPV	O
)	O
were	O
higher	O
for	O
oral	O
HPV	O
16	O
compared	O
to	O
oral	O
oncogenic	O
HPV	O
.	O

Variables	O
contributing	O
to	O
oral	O
gargle	O
-	O
tumor	O
specimen	O
HPV	O
status	O
agreement	O

In	O
the	O
ﬁnal	O
multivariable	O
logistic	O
model	O
only	O
three	O
variables	O
were	O
independently	O
associated	O
with	O
oral	O
gargle	O
-	O
tumor	O
biopsy	O
agreement	O
for	O

any	O
oncogenic	O
HPV	O
type	O
.	O

Age	O
50	O
or	O
older	O
at	O
diagnosis	O
(	O
multivariable	O
adjusted	O
odds	O
ratio	O
[	O
aOR	O
]	O
for	O
ages	O
50–59	O
,	O
60–69	O
,	O
and	O
≥70	O
years	O
was	O
5	O
.	O
78	O
,	O
11	O
.	O
97	O
,	O
and	O
4	O
.	O
46	O
,	O
respectively	O
,	O
compared	O
to	O
ages	O
35–49	O
years	O
)	O
and	O
late	O
disease	O
at	O
presentation	O
(	O
aOR	O
2	O
.	O
81	O
;	O
95	O
%	O
CI	O
1	O
.	O
14	O
,	O
6	O
.	O
95	O
)	O
were	O
both	O
signiﬁcantly	O
associated	O
with	O
higher	O
odds	O
of	O
agreement	O
.	O

In	O
contrast	O
,	O
tonsillectomy	O
was	O
associated	O
with	O
signiﬁcantly	O
lower	O
odds	O
of	O
oral	O
gargle	O
-	O
tumor	O
biopsy	O
oncogenic	O
HPV	O
agreement	O
(	O
aOR	O
0	O
.	O
40	O
;	O
95	O
%	O
CI	O
0	O
.	O
17	O
,	O
0	O
.	O
91	O
)	O
(	O
)	O
.	O

Only	O
ages	O
60–69	O
years	O
(	O
aOR	O
6	O
.	O
69	O
compared	O
to	O
age	O
35–49	O
years	O
)	O
and	O
late	O
disease	O
at	O
presentation	O
(	O
aOR	O
2	O
.	O
95	O
;	O
95	O
%	O
CI	O
1	O
.	O
23	O
,	O
7	O
.	O
11	O
)	O
were	O
signiﬁcantly	O
associated	O
with	O
oral	O
gargle	O
-	O
tumor	O
biopsy	O
HPV	O
16	O
agreement	O
in	O
the	O
ﬁnal	O
multivariable	O
logistic	O
model	O
(	O
)	O
.	O

